CHILDRENS CANCER GROUP

该项目建议继续在儿童医院洛杉矶（CHLA）的综合儿科肿瘤学计划。 该计划旨在通过作为儿童癌症小组（CCG）的成员进行临床研究以及独立进行与CCG的使命直接相关的其他研究来改善癌症儿童的治疗。CHLA是太平洋西南地区的一个主要儿科转诊中心，拥有全国最大的儿科肿瘤服务之一。 一个跨部门的计划已经发展，涉及基础和临床科学家，并已演变成一个多学科的模式，为儿童癌症的管理。CHLA是CCG研究患者的主要贡献者之一，该机构的多学科工作人员参与CCG的所有活动。 CHLA研究人员参与CCG，可以进行定量比较临床研究，旨在建立任何癌症治疗的最佳模式。 CHLA的独特资源允许开发新的治疗方法用于全集团应用。 这些包括参与白血病/淋巴瘤、神经肿瘤、骨和软组织肿瘤和长期随访计划;评价新的剂量方案和体外和体内药理学研究预测的既定药物组合;调查耐药性机制;骨髓外周血和脐带干细胞移植;选定肿瘤的免疫学特征;癌症及其治疗对儿童恶性肿瘤造血最佳营养支持的影响;儿科癌症患者和家庭的心理社会康复方法;护理人员和患者/家庭的教育;儿童恶性肿瘤的流行病学;分子和细胞药理学的临床前研究;肿瘤细胞生物学;致癌作用和化学预防;细胞遗传学;以及体外和体内肿瘤模型系统。 社区医生网络在CHLA的赞助下参与CCG，使未被转诊接受初步癌症护理的儿童能够使用最佳治疗。 该项目还为少数民族患者继续参加CCG临床试验提供了条件。 通过拟议的更新，CHLA的综合方案将寻求作为其最终目标的综合和调查方法，以儿童癌症。

The project proposes continuation of a comprehensive pediatric oncology program at Childrens Hospital Los Angeles (CHLA). This program is designed to improve the treatment of children with cancer by conducting clinical investigations as a member of the Childrens Cancer Group (CCG) and by independently conducting other research which is directly related to the mission of CCG. CHLA is a major pediatric referral center for the Pacific Southwest and has one of the largest pediatric oncology services in the nation. An interdepartmental program has developed which involves basic and clinical scientists and has evolved into a multidisciplinary model for the management of pediatric cancers. CHLA is one of the major contributors of patients to CCG studies and the multidisciplinary staff at this institution participate in all activities of CCG. Participation of CHLA investigators in CCG enables quantitative comparative clinical investigations aimed at establishing the best mode of any cancer therapy. The unique resources of CHLA permit development of new therapeutic approaches for Group-wide application. These include participation in the Leukemia/Lymphoma, Neuro-Oncology, Bone and Soft Tissue Tumor, and Long-Term Followup Programs; the evaluation of new dose schedules and combinations of established agents predicted by in vitro and in vivo pharmacological studies; investigation of mechanisms of drug resistance; bone marrow peripheral blood and umbilical cord stem cell transplantation; immunological characterization of selected neoplasms; effects of cancer and its treatment on hematopoiesis optimum nutritional support in childhood malignancies; approaches to psychosocial rehabilitation of the pediatric cancer patient and family; education of caregivers and patients/families; epidemiology of childhood malignancies; preclinical studies in molecular and cellular pharmacology; tumor cell biology; carcinogenesis and chemoprevention; cytogenetics; and in vitro and in vivo tumor model systems. A network of community physicians participate in the CCG under the sponsorship of CHLA which enables the use of optimal therapy in children who are not referred for initial cancer care. The project also provides continuation of entry of minority patients on CCG clinical trials. Through the proposed renewal, the comprehensive program at CHLA will seek as its ultimate goal an integrated and investigative approach to childhood cancer.